{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T04:00:28Z","timestamp":1792814428698,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T00:00:00Z","timestamp":1679097600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014717","name":"National Outstanding Youth Science Fund Project of National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["72004151"],"award-info":[{"award-number":["72004151"]}],"id":[{"id":"10.13039\/100014717","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Science and Technology Plan Project of Sichuan Province","award":["2020YFS0035"],"award-info":[{"award-number":["2020YFS0035"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Though triazole antifungals are the first choice for preventing and treating invasive fungal infections, periostitis caused by voriconazole has been described in emerging case reports; however, no studies exist on this association in real-world clinical settings. Our study aimed to identify the association between periostitis and triazole antifungals by analyzing data from the FDA Adverse Event Reporting System (FAERS). We extracted and analyzed reports on the association between periostitis and triazole antifungals in FAERS from the first quarter of 2004 to the second quarter of 2022 using OpenVigil 2.1. Disproportionality analysis was performed to evaluate the association between periostitis and triazole antifungals, and chi-squared (\u03c7<jats:sup>2<\/jats:sup>), relative reporting ratio (RRR), reporting odds ratio (ROR), proportional reporting ratio (PRR), and Bayesian confidence propagation neural networks (BCPNN) of information components (IC) were reported. In total, 143 patients experienced periostitis while using voriconazole. Disproportionality analysis identified an association between periostitis and voriconazole (\u03c7<jats:sup>2<\/jats:sup>\u2009=\u200982,689.0, RRR\u2009=\u2009583.6, 95%CI [472.4, 721.1], PRR\u2009=\u20091808.9, 95%CI [1356.0, 2412.9], ROR\u2009=\u20091831.7, 95%CI [1371.6, 2446.3], IC\u2009=\u20099.2, 95%CI [8.6, 9.8]). However, no safety signals were observed between periostitis and other triazole antifungals. When stratified by sex and age, disproportionality analysis identified positive signals between periostitis and voriconazole. The possible association between periostitis and voriconazole should attract sufficient attention in clinical practice. Alternative treatment with other triazole antifungals can be considered, and causality needs to be verified in further prospective studies.<\/jats:p>","DOI":"10.1038\/s41598-023-27687-0","type":"journal-article","created":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T18:02:38Z","timestamp":1679162558000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Using disproportionality analysis to explore the association between periostitis and triazole antifungals in the FDA Adverse Event Reporting System Database"],"prefix":"10.1038","volume":"13","author":[{"given":"Hailong","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuefeng","family":"Jiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linan","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huiqing","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,3,18]]},"reference":[{"key":"27687_CR1","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/cid\/ciw444","volume":"63","author":"TF Patterson","year":"2016","unstructured":"Patterson, T. F. et al. Executive summary: Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases society of America. Clin. Infect. Dis. 63, 433\u2013442 (2016).","journal-title":"Clin. Infect. Dis."},{"key":"27687_CR2","doi-asserted-by":"publisher","first-page":"e13544","DOI":"10.1111\/ctr.13544","volume":"33","author":"S Husain","year":"2019","unstructured":"Husain, S. & Camargo, J. F. Invasive aspergillosis in solid-organ transplant recipients: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin. Transplant. 33, e13544 (2019).","journal-title":"Clin. Transplant."},{"key":"27687_CR3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1148\/radiol.14122800","volume":"274","author":"TD Tailor","year":"2015","unstructured":"Tailor, T. D. & Richardson, M. L. Case 215: Voriconazole-induced periostitis. Radiology 274, 930\u2013935 (2015).","journal-title":"Radiology"},{"key":"27687_CR4","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1503\/cmaj.141025","volume":"187","author":"T Glushko","year":"2015","unstructured":"Glushko, T. & Colmegna, I. Voriconazole-induced periostitis. CMAJ 187, 1075 (2015).","journal-title":"CMAJ"},{"key":"27687_CR5","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/ajh.23977","volume":"90","author":"JH Baird","year":"2015","unstructured":"Baird, J. H., Birnbaum, B. K., Porter, D. L. & Frey, N. V. Voriconazole-induced periostitis after allogeneic stem cell transplantation. Am. J. Hematol. 90, 574\u2013575 (2015).","journal-title":"Am. J. Hematol."},{"key":"27687_CR6","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2013-203485","author":"K Hirota","year":"2014","unstructured":"Hirota, K., Yasoda, A., Fujii, T. & Inagaki, N. Voriconazole-induced periostitis in a patient with overlap syndromes. BMJ Case Rep. https:\/\/doi.org\/10.1136\/bcr-2013-203485 (2014).","journal-title":"BMJ Case Rep."},{"key":"27687_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s00259-011-1922-x","volume":"39","author":"C Rossier","year":"2012","unstructured":"Rossier, C. et al. Voriconazole-induced periostitis. Eur. J. Nucl. Med. Mol. Imaging 39, 375\u2013376 (2012).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"27687_CR8","doi-asserted-by":"publisher","first-page":"3490","DOI":"10.1002\/art.34618","volume":"64","author":"F Becce","year":"2012","unstructured":"Becce, F., Malghem, J., Lecouvet, F. E., Vande Berg, B. C. & Omoumi, P. Clinical images: Voriconazole-induced periostitis deformans. Arthritis Rheum. 64, 3490 (2012).","journal-title":"Arthritis Rheum."},{"key":"27687_CR9","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1097\/RLU.0b013e31820902d8","volume":"36","author":"SM Wise","year":"2011","unstructured":"Wise, S. M. & Wilson, M. A. A case of periostitis secondary to voriconazole therapy in a heart transplant recipient. Clin. Nucl. Med. 36, 242\u2013244 (2011).","journal-title":"Clin. Nucl. Med."},{"key":"27687_CR10","doi-asserted-by":"publisher","first-page":"e779","DOI":"10.1200\/JCO.2011.35.9604","volume":"29","author":"JL Skiles","year":"2011","unstructured":"Skiles, J. L., Imel, E. A., Christenson, J. C., Bell, J. E. & Hulbert, M. L. Fluorosis because of prolonged voriconazole therapy in a teenager with acute myelogenous leukemia. J. Clin. Oncol. 29, e779\u2013e782 (2011).","journal-title":"J. Clin. Oncol."},{"key":"27687_CR11","doi-asserted-by":"publisher","first-page":"e793","DOI":"10.3928\/01477447-20110922-35","volume":"34","author":"DP Lustenberger","year":"2011","unstructured":"Lustenberger, D. P., Granata, J. D. & Scharschmidt, T. J. Periostitis secondary to prolonged voriconazole therapy in a lung transplant recipient. Orthopedics 34, e793\u2013e796 (2011).","journal-title":"Orthopedics"},{"key":"27687_CR12","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1097\/RHU.0b013e31820aff12","volume":"17","author":"A Ayub","year":"2011","unstructured":"Ayub, A., Kenney, C. V. & McKiernan, F. E. Multifocal nodular periostitis associated with prolonged voriconazole therapy in a lung transplant recipient. J. Clin. Rheumatol. 17, 73\u201375 (2011).","journal-title":"J. Clin. Rheumatol."},{"key":"27687_CR13","doi-asserted-by":"publisher","first-page":"e30","DOI":"10.1056\/NEJMicm1814565","volume":"381","author":"J Hedrick","year":"2019","unstructured":"Hedrick, J. & Droz, N. Voriconazole-induced periostitis. N. Engl. J. Med. 381, e30 (2019).","journal-title":"N. Engl. J. Med."},{"key":"27687_CR14","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1093\/cid\/ciu513","volume":"59","author":"WJ Moon","year":"2014","unstructured":"Moon, W. J. et al. Plasma fluoride level as a predictor of voriconazole-induced periostitis in patients with skeletal pain. Clin. Infect. Dis. 59, 1237\u20131245 (2014).","journal-title":"Clin. Infect. Dis."},{"key":"27687_CR15","doi-asserted-by":"publisher","first-page":"356","DOI":"10.5500\/wjt.v11.i9.356","volume":"11","author":"AJ Guarascio","year":"2021","unstructured":"Guarascio, A. J., Bhanot, N. & Min, Z. Voriconazole-associated periostitis: Pathophysiology, risk factors, clinical manifestations, diagnosis, and management. World J. Transplant. 11, 356\u2013371 (2021).","journal-title":"World J. Transplant."},{"key":"27687_CR16","doi-asserted-by":"publisher","first-page":"21","DOI":"10.2174\/1574886313666181026100000","volume":"14","author":"V Subeesh","year":"2019","unstructured":"Subeesh, V., Maheswari, E., Singh, H., Beulah, T. E. & Swaroop, A. M. Novel adverse events of iloperidone: A disproportionality analysis in US food and drug administration adverse event reporting system (FAERS) database. Curr. Drug Saf. 14, 21\u201326 (2019).","journal-title":"Curr. Drug Saf."},{"key":"27687_CR17","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1093\/jamia\/ocv063","volume":"23","author":"HJ Duggirala","year":"2016","unstructured":"Duggirala, H. J. et al. Use of data mining at the food and drug administration. J. Am. Med. Inform. Assoc. 23, 428\u2013434 (2016).","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"27687_CR18","doi-asserted-by":"publisher","first-page":"4803","DOI":"10.1038\/s41598-020-61571-5","volume":"10","author":"J Huang","year":"2020","unstructured":"Huang, J. et al. Safety profile of epidermal growth factor receptor tyrosine kinase inhibitors: A disproportionality analysis of FDA adverse event reporting system. Sci. Rep. 10, 4803 (2020).","journal-title":"Sci. Rep."},{"key":"27687_CR19","doi-asserted-by":"publisher","first-page":"3116","DOI":"10.1038\/s41598-020-60068-5","volume":"10","author":"N Han","year":"2020","unstructured":"Han, N., Oh, J. M. & Kim, I. W. Assessment of adverse events related to anti-influenza neuraminidase inhibitors using the FDA adverse event reporting system and online patient reviews. Sci. Rep. 10, 3116 (2020).","journal-title":"Sci. Rep."},{"key":"27687_CR20","unstructured":"Jakobsen, D. M., Justad, B. A., Helweg-Larsen, J. & Katzenstein, T. L. Voriconazole-induced periostitis. Ugeskr. laeger 181, 1\u20133 (2019)."},{"key":"27687_CR21","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1182\/blood-2012-01-403030","volume":"120","author":"B Gerber","year":"2012","unstructured":"Gerber, B. et al. Reversible skeletal disease and high fluoride serum levels in hematologic patients receiving voriconazole. Blood 120, 2390\u20132394 (2012).","journal-title":"Blood"},{"key":"27687_CR22","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1093\/cid\/ciq188","volume":"52","author":"RA Wermers","year":"2011","unstructured":"Wermers, R. A. et al. Fluoride excess and periostitis in transplant patients receiving long-term voriconazole therapy. Clin. Infect. Dis. 52, 604\u2013611 (2011).","journal-title":"Clin. Infect. Dis."},{"key":"27687_CR23","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1007\/s00256-010-0997-y","volume":"40","author":"L Chen","year":"2011","unstructured":"Chen, L. & Mulligan, M. E. Medication-induced periostitis in lung transplant patients: Periostitis deformans revisited. Skelet. Rad. 40, 143\u2013148 (2011).","journal-title":"Skelet. Rad."},{"issue":"6","key":"27687_CR24","doi-asserted-by":"publisher","first-page":"bbab347","DOI":"10.1093\/bib\/bbab347","volume":"22","author":"Y Noguchi","year":"2021","unstructured":"Noguchi, Y., Tachi, T. & Teramachi, H. Detection algorithms and attentive points of safety signal using spontaneous reporting systems as a clinical data source. Brief. Bioinform. 22(6), bbab347 (2021).","journal-title":"Brief. Bioinform."},{"key":"27687_CR25","unstructured":"FDA Adverse Event Reporting System (FAERS) Public Dashboard. https:\/\/www.fda.gov\/drugs\/questions-and-answers-fdas-adverse-event-reporting-system-faers\/fda-adverse-event-reportingsystem-faers-public-dashboard (2018).\nAccessed 1 December 2022."},{"key":"27687_CR26","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nbt.2113","volume":"30","author":"R B\u00f6hm","year":"2012","unstructured":"B\u00f6hm, R., H\u00f6cker, J., Cascorbi, I. & Herdegen, T. OpenVigil\u2013Free eyeballs on AERS pharmacovigilance data. Nat. Biotechnol. 30, 137\u2013138 (2012).","journal-title":"Nat. Biotechnol."},{"key":"27687_CR27","unstructured":"Br\u00f6han, R. & Steglich, M. OpenVigil 2 tutorial. https:\/\/openvigil.sourceforge.net\/doc\/OpenVigil2-Tutorial.pdf (2015). Accessed 1 December 2022."},{"key":"27687_CR28","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1002\/phar.1519","volume":"34","author":"TM Khadem","year":"2014","unstructured":"Khadem, T. M., van Manen, R. P. & Brown, J. How safe are recently FDA-approved antimicrobials? A review of the FDA Adverse Event Reporting System Database. Pharmacotherapy 34, 1324\u20131329 (2014).","journal-title":"Pharmacotherapy"},{"key":"27687_CR29","doi-asserted-by":"publisher","first-page":"4421","DOI":"10.1111\/bcp.14868","volume":"87","author":"R B\u00f6hm","year":"2021","unstructured":"B\u00f6hm, R. et al. Pharmacovigilance-based drug repurposing: The search for inverse signals via OpenVigil identifies putative drugs against viral respiratory infections. Br. J. Clin. Pharmacol. 87, 4421\u20134431 (2021).","journal-title":"Br. J. Clin. Pharmacol."},{"key":"27687_CR30","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jaad.2020.08.013","volume":"85","author":"D Duron","year":"2021","unstructured":"Duron, D., Blaise, S., Cracowski, J. L., Roustit, M. & Khouri, C. Drug-induced skin ulcers: A disproportionality analysis from the WHO pharmacovigilance database. J. Am. Acad. Dermatol. 85, 229\u2013232 (2021).","journal-title":"J. Am. Acad. Dermatol."},{"key":"27687_CR31","doi-asserted-by":"publisher","first-page":"2101576","DOI":"10.1183\/13993003.01576-2021","volume":"58","author":"C Khouri","year":"2021","unstructured":"Khouri, C. et al. Investigating the association between ALK receptor tyrosine kinase inhibitors and pulmonary arterial hypertension: A disproportionality analysis from the WHO pharmacovigilance database. Eur. Respir. J. 58, 2101576 (2021).","journal-title":"Eur. Respir. J."},{"key":"27687_CR32","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.677","volume":"10","author":"SJ Evans","year":"2001","unstructured":"Evans, S. J., Waller, P. C. & Davis, S. Use of proportional reporting ratios (PRRs) for signal generation from spontaneous adverse drug reaction reports. Pharmacoepidemiol. Drug Saf. 10, 483\u2013486 (2001).","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"27687_CR33","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1159\/000510703","volume":"90","author":"C Gastaldon","year":"2021","unstructured":"Gastaldon, C., Raschi, E., Kane, J. M., Barbui, C. & Schoretsanitis, G. Post-marketing safety concerns with esketamine: A disproportionality analysis of spontaneous reports submitted to the FDA adverse event reporting system. Psychother. Psychosom. 90, 41\u201348 (2021).","journal-title":"Psychother. Psychosom."},{"key":"27687_CR34","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/nbt.2113","volume":"81","author":"R Morris","year":"2021","unstructured":"Morris, R. et al. Bradycardia due to donepezil in adults: Systematic analysis of FDA adverse event reporting system. J. Alzheimers Dis. 81, 297\u2013307. https:\/\/doi.org\/10.1038\/nbt.2113 (2021).","journal-title":"J. Alzheimers Dis."},{"key":"27687_CR35","doi-asserted-by":"publisher","first-page":"11955","DOI":"10.1038\/s41598-020-68906-2","volume":"10","author":"XF Jiao","year":"2020","unstructured":"Jiao, X. F. et al. Ovary and uterus related adverse events associated with statin use: An analysis of the FDA adverse event reporting system. Sci. Rep. 10, 11955 (2020).","journal-title":"Sci. Rep."},{"key":"27687_CR36","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1007\/s11096-021-01273-8","volume":"43","author":"M Guo","year":"2021","unstructured":"Guo, M. et al. Evaluation of rivaroxaban-, apixaban- and dabigatran-associated hemorrhagic events using the FDA adverse event reporting system (FAERS) database. Int. J. Clin. Pharm. 43, 1508\u20131515 (2021).","journal-title":"Int. J. Clin. Pharm."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27687-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27687-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,18]],"date-time":"2023-03-18T18:02:55Z","timestamp":1679162575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-023-27687-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,18]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["27687"],"URL":"https:\/\/doi.org\/10.1038\/s41598-023-27687-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,18]]},"assertion":[{"value":"19 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 January 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"4475"}}